VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.45%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$3.44M
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$670K |
| 2 |
Zai Lab
ZLAB
|
$520K |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$422K |
| 4 |
DRD
DRDGold
DRD
|
$405K |
| 5 |
Stellus Capital Investment Corp
SCM
|
$402K |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
$1.28M |
| 2 |
Prothena Corp
PRTA
|
$971K |
| 3 |
BioNTech
BNTX
|
$787K |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$647K |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$645K |
Sector Composition
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TBIO
201
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $290K | 0.12% |
10,536
-624
| -6% | -$17.2K |
|
202
MacroGenics
MGNX
$126M
| $289K | 0.12% |
10,754
-1,894
| -15% | -$50.9K |
|
203
CRISPR Therapeutics
CRSP
$4.99B
| $281K | 0.12% |
1,737
-266
| -13% | -$43K |
|
204
Celldex Therapeutics
CLDX
$1.52B
| $278K | 0.11% |
8,300
-8,164
| -50% | -$273K |
|
205
Nkarta
NKTX
$161M
| $264K | 0.11% |
8,337
+4,026
| +93% | +$127K |
|
|
IMAB
206
I-MAB
IMAB
$358M
| $259K | 0.11% |
3,086
-4,774
| -61% | -$401K |
|
207
Seres Therapeutics
MCRB
$169M
| $258K | 0.11% |
541
-64
| -11% | -$30.5K |
|
208
Cassava Sciences
SAVA
$104M
| $252K | 0.1% |
+2,951
| New | +$252K |
|
|
INBX
209
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $252K | 0.1% |
9,153
+1,885
| +26% | +$51.9K |
|
210
Arcus Biosciences
RCUS
$1.3B
| $250K | 0.1% |
9,111
-237
| -3% | -$6.5K |
|
|
FIV
211
DELISTED
First Trust Senior Floating Rate 2022 Target Term Fund Common Shares of Beneficial Interest
FIV
| $250K | 0.1% |
26,230
+6,818
| +35% | +$65K |
|
212
Crescent Capital BDC
CCAP
$591M
| $249K | 0.1% |
13,248
+3,357
| +34% | +$63.1K |
|
213
Quince Therapeutics
QNCX
$86.5M
| $249K | 0.1% |
4,703
-5,274
| -53% | -$279K |
|
214
Replimune Group
REPL
$494M
| $248K | 0.1% |
6,452
-435
| -6% | -$16.7K |
|
215
Kodiak Sciences
KOD
$556M
| $245K | 0.1% |
2,636
+328
| +14% | +$30.5K |
|
216
Dynavax Technologies
DVAX
$1.18B
| $244K | 0.1% |
24,799
-33,291
| -57% | -$328K |
|
217
Iovance Biotherapeutics
IOVA
$901M
| $244K | 0.1% |
9,371
+3,400
| +57% | +$88.5K |
|
218
Protagonist Therapeutics
PTGX
$3.77B
| $244K | 0.1% |
5,441
-8,905
| -62% | -$399K |
|
219
Carisma Therapeutics
CARM
$16.8M
| $243K | 0.1% |
+2,632
| New | +$243K |
|
|
PSTX
220
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $243K | 0.1% |
+24,287
| New | +$243K |
|
221
Precision BioSciences
DTIL
$59.8M
| $241K | 0.1% |
642
-604
| -48% | -$227K |
|
|
222
Prothena Corp
PRTA
$460M
| $241K | 0.1% |
4,694
-18,904
| -80% | -$971K |
|
223
AC Immune
ACIU
$229M
| $239K | 0.1% |
+30,187
| New | +$239K |
|
|
AGEN
224
Agenus
AGEN
$138M
| $239K | 0.1% |
2,217
-1,952
| -47% | -$210K |
|
225
Relay Therapeutics
RLAY
$710M
| $239K | 0.1% |
6,544
-305
| -4% | -$11.1K |
|